-+ 0.00%
-+ 0.00%
-+ 0.00%

Altimmune Publishes IMPACT Phase 2b 48-Week Data In The Lancet Gastroenterology & Hepatology

Benzinga·11/12/2026 12:22:25
Listen to the news

 

Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile

Publication of results provides further validation for the balanced 1:1 glucagon/GLP-1 dual receptor agonist profile of pemvidutide